Masanori Kawakami1, Lisa Maria Mustachio1, Jaime Rodriguez-Canales2, Barbara Mino2, Jason Roszik3,4, Pan Tong5, Jing Wang5, J Jack Lee6, Ja Hye Myung7, John V Heymach8, Faye M Johnson1, Seungpyo Hong7, Lin Zheng1, Shanhu Hu9, Pamela Andrea Villalobos2, Carmen Behrens1, Ignacio Wistuba2, Sarah Freemantle9, Xi Liu1, Ethan Dmitrovsky1,8,9. 1. Departments of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 2. Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 3. Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 4. Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 5. Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 7. Department of Biopharmaceutical Sciences, College of Pharmacy, The University of Illinois, Chicago, IL, USA. 8. Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 9. Department of Pharmacology and Toxicology, Geisel School of Medicine at Dartmouth, Hanover, NH, USA.
Abstract
Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel). Methods: CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murine lung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided. Results: CCT68127 inhibited growth up to 88.5% (SD = 6.4%, P < .003) at 1 μM, induced apoptosis up to 42.6% (SD = 5.5%, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6%, SD = 3.6%, P = .32; apoptosis at 2 μM: 8.2%, SD = 1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD = 3.6%, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70% (SD = 3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065. Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.
Background: The first generation CDK2/7/9 inhibitor seliciclib (CYC202) causes multipolar anaphase and apoptosis in lung cancer cells with supernumerary centrosomes (known as anaphase catastrophe). We investigated a new and potent CDK2/9 inhibitor, CCT68127 (Cyclacel). Methods:CCT68127 was studied in lung cancer cells (three murine and five human) and control murine pulmonary epithelial and human immortalized bronchial epithelial cells. Robotic CCT68127 cell-based proliferation screens were used. Cells undergoing multipolar anaphase and inhibited centrosome clustering were scored. Reverse phase protein arrays (RPPAs) assessed CCT68127 effects on signaling pathways. The function of PEA15, a growth regulator highlighted by RPPAs, was analyzed. Syngeneic murinelung cancer xenografts (n = 4/group) determined CCT68127 effects on tumorigenicity and circulating tumor cell levels. All statistical tests were two-sided. Results:CCT68127 inhibited growth up to 88.5% (SD = 6.4%, P < .003) at 1 μM, induced apoptosis up to 42.6% (SD = 5.5%, P < .001) at 2 μM, and caused G1 or G2/M arrest in lung cancer cells with minimal effects on control cells (growth inhibition at 1 μM: 10.6%, SD = 3.6%, P = .32; apoptosis at 2 μM: 8.2%, SD = 1.0%, P = .22). A robotic screen found that lung cancer cells with KRAS mutation were particularly sensitive to CCT68127 ( P = .02 for IC 50 ). CCT68127 inhibited supernumerary centrosome clustering and caused anaphase catastrophe by 14.1% (SD = 3.6%, P < .009 at 1 μM). CCT68127 reduced PEA15 phosphorylation by 70% (SD = 3.0%, P = .003). The gain of PEA15 expression antagonized and its loss enhanced CCT68127-mediated growth inhibition. CCT68127 reduced lung cancer growth in vivo ( P < .001) and circulating tumor cells ( P = .004). Findings were confirmed with another CDK2/9 inhibitor, CYC065. Conclusions: Next-generation CDK2/9 inhibition elicits marked antineoplastic effects in lung cancer via anaphase catastrophe and reduced PEA15 phosphorylation.
Authors: Ja Hye Myung; Monic Roengvoraphoj; Kevin A Tam; Tian Ma; Vincent A Memoli; Ethan Dmitrovsky; Sarah J Freemantle; Seungpyo Hong Journal: Anal Chem Date: 2015-09-10 Impact factor: 6.986
Authors: Raoul Tibes; Yihua Qiu; Yiling Lu; Bryan Hennessy; Michael Andreeff; Gordon B Mills; Steven M Kornblau Journal: Mol Cancer Ther Date: 2006-10 Impact factor: 6.261
Authors: Zhen Tao; Justin M Le Blanc; Chenguang Wang; Tingting Zhan; Hongqing Zhuang; Ping Wang; Zhiyong Yuan; Bo Lu Journal: Clin Cancer Res Date: 2016-01-01 Impact factor: 12.531
Authors: Xi Liu; Lorenzo F Sempere; Haoxu Ouyang; Vincent A Memoli; Angeline S Andrew; Yue Luo; Eugene Demidenko; Murray Korc; Wei Shi; Meir Preis; Konstantin H Dragnev; Hua Li; James Direnzo; Mads Bak; Sarah J Freemantle; Sakari Kauppinen; Ethan Dmitrovsky Journal: J Clin Invest Date: 2010-03-08 Impact factor: 14.808
Authors: Alexey V Danilov; Shanhu Hu; Bernardo Orr; Kristina Godek; Lisa Maria Mustachio; David Sekula; Xi Liu; Masanori Kawakami; Faye M Johnson; Duane A Compton; Sarah J Freemantle; Ethan Dmitrovsky Journal: Mol Cancer Ther Date: 2016-08-22 Impact factor: 6.261
Authors: A Eckert; B C Böck; K E Tagscherer; T L Haas; K Grund; J Sykora; C Herold-Mende; V Ehemann; M Hollstein; H Chneiweiss; O D Wiestler; H Walczak; W Roth Journal: Oncogene Date: 2007-08-13 Impact factor: 9.867
Authors: Sarah J Freemantle; Xi Liu; Qing Feng; Fabrizio Galimberti; Steven Blumen; David Sekula; Sutisak Kitareewan; Konstantin H Dragnev; Ethan Dmitrovsky Journal: J Cell Biochem Date: 2007-11-01 Impact factor: 4.429
Authors: Masanori Kawakami; Lisa Maria Mustachio; Lin Zheng; Yulong Chen; Jaime Rodriguez-Canales; Barbara Mino; Jonathan M Kurie; Jason Roszik; Pamela Andrea Villalobos; Kelsie L Thu; Jennifer Silvester; David W Cescon; Ignacio I Wistuba; Tak W Mak; Xi Liu; Ethan Dmitrovsky Journal: Proc Natl Acad Sci U S A Date: 2018-02-06 Impact factor: 11.205
Authors: Jason A Somarelli; Roham Salman Roghani; Ali Sanjari Moghaddam; Beatrice C Thomas; Gabrielle Rupprecht; Kathryn E Ware; Erdem Altunel; John B Mantyh; So Young Kim; Shannon J McCall; Xiling Shen; Christopher R Mantyh; David S Hsu Journal: Mol Cancer Ther Date: 2020-11-06 Impact factor: 6.261
Authors: Lisa Maria Mustachio; Jason Roszik; Aimee T Farria; Karla Guerra; Sharon Yr Dent Journal: Am J Cancer Res Date: 2019-08-01 Impact factor: 6.166
Authors: Masanori Kawakami; Lisa Maria Mustachio; Yulong Chen; Zibo Chen; Xiuxia Liu; Cheng-Hsin Wei; Jason Roszik; Adam S Kittai; Alexey V Danilov; Xiaoshan Zhang; Bingliang Fang; Jing Wang; John V Heymach; Liliya Tyutyunyk-Massey; Sarah J Freemantle; Jonathan M Kurie; Xi Liu; Ethan Dmitrovsky Journal: Mol Cancer Ther Date: 2020-12-04 Impact factor: 6.261
Authors: Xi Liu; Yun Lu; Zibo Chen; Xiuxia Liu; Weiguo Hu; Lin Zheng; Yulong Chen; Jonathan M Kurie; Mi Shi; Lisa Maria Mustachio; Thorkell Adresson; Stephen Fox; Jason Roszik; Masanori Kawakami; Sarah J Freemantle; Ethan Dmitrovsky Journal: Mol Cancer Res Date: 2020-12-30 Impact factor: 6.333